Abstract
Cytochrome P450 (CYP) enzymes are a superfamily of heme containing proteins that catalyze xenobiotic metabolism phase I reactions. Oxidation reactions are the most common CYP-catalyzed reactions for both endogenous substrates and exogenous compounds, including drugs, although CYP enzymes are capable also to catalyze reduction reactions. Whereas the majority of clinically used drugs are inactivated by CYPs, several prodrugs are bioconverted to their active species by these enzymes. Therefore, this mechanism could be exploited to a greater extend, e.g. by taking advantage of the different CYP enzymes to achieve targeted drug delivery, to improve efficacy or to decrease the unwanted adverse effects of existing and novel drug molecules. This review describes the potential of CYP enzymes in prodrug design and summarizes a wide variety of CYP-activated prodrug structures, which are on the market or under the development. The bioactivation mechanisms of each CYP-activated prodrug structure are described and the specificity for the different forms of CYP enzymes is discussed.
Keywords: Antibody-directed enzyme prodrug therapy (ADEPT), cyclic phosphate, cytochrome P450 enzyme, gene-directed enzyme prodrug therapy (GDEPT), N-oxide, nucleoside, oxazaphosphorine, oxime, prodrug, targeted drug delivery
Current Medicinal Chemistry
Title: Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Volume: 15 Issue: 23
Author(s): Kristiina M. Huttunen, Niina Mahonen, Hannu Raunio and Jarkko Rautio
Affiliation:
Keywords: Antibody-directed enzyme prodrug therapy (ADEPT), cyclic phosphate, cytochrome P450 enzyme, gene-directed enzyme prodrug therapy (GDEPT), N-oxide, nucleoside, oxazaphosphorine, oxime, prodrug, targeted drug delivery
Abstract: Cytochrome P450 (CYP) enzymes are a superfamily of heme containing proteins that catalyze xenobiotic metabolism phase I reactions. Oxidation reactions are the most common CYP-catalyzed reactions for both endogenous substrates and exogenous compounds, including drugs, although CYP enzymes are capable also to catalyze reduction reactions. Whereas the majority of clinically used drugs are inactivated by CYPs, several prodrugs are bioconverted to their active species by these enzymes. Therefore, this mechanism could be exploited to a greater extend, e.g. by taking advantage of the different CYP enzymes to achieve targeted drug delivery, to improve efficacy or to decrease the unwanted adverse effects of existing and novel drug molecules. This review describes the potential of CYP enzymes in prodrug design and summarizes a wide variety of CYP-activated prodrug structures, which are on the market or under the development. The bioactivation mechanisms of each CYP-activated prodrug structure are described and the specificity for the different forms of CYP enzymes is discussed.
Export Options
About this article
Cite this article as:
Huttunen M. Kristiina, Mahonen Niina, Raunio Hannu and Rautio Jarkko, Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery, Current Medicinal Chemistry 2008; 15 (23) . https://dx.doi.org/10.2174/092986708785909120
DOI https://dx.doi.org/10.2174/092986708785909120 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine
Current Cancer Drug Targets Indole Derivatives as Anti-Tubercular Agents: An Overview on their Synthesis and Biological Activities
Current Medicinal Chemistry The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Viruses and Oral Cancer: Crossreactivity as a Potential Link
Anti-Cancer Agents in Medicinal Chemistry Ubiquitylation and Cancer Development
Current Cancer Drug Targets Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Endogenous Enzyme-responsive Nanoplatforms for Anti-tumor Therapy
Current Drug Targets Chemotherapy for Laryngeal Cancer - An Apoptotic Approach
Current Drug Targets Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies
Current Radiopharmaceuticals Advances in Chondroitin Sulfate Analysis: Application in Physiological and Pathological States of Connective Tissue and During Pharmacological Treatment of Osteoarthritis
Current Pharmaceutical Design A Survey on Synthesis Processes of Structured Materials for Biomedical Applications: Iron-based Magnetic Nanoparticles, Polymeric Materials and Polymerization Processes
Current Pharmaceutical Design Tumor Stroma as a Target in Cancer
Current Cancer Drug Targets Modulation of DNA Damage Checkpoint; Patenting and Possible Application for Cancer Medicine
Recent Patents on DNA & Gene Sequences Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry